Osteologix, Inc. (OTCBB:OLGX) today announced that in light of recent announcements and set-backs in the field of Osteoporosis, the company believes it is positioned to take advantage of a significant gap in the market, and will discuss its development of a safe and effective treatment for Osteoporosis at the Rodman and Renshaw 11th Annual Healthcare Conference. Philip J. Young, President and CEO of Osteologix, will present the company’s corporate overview at 10:50 a.m. ET on Wednesday, September 9, at the New York Palace Hotel in New York City. The live audio webcast and slide presentation can be accessed by visiting www.osteologix.com and clicking the link provided under “Latest News”.
About Osteologix
Osteologix is a specialty biopharmaceutical company committed to improving the health of those afflicted with musculoskeletal diseases, such as osteoporosis, by developing innovative therapies. Its lead investigational product candidate, NB S101, is a novel pharmaceutical agent for the treatment and prevention of osteoporosis. For more information please visit www.osteologix.com.
Contacts:
Osteologix, Inc.
Investor and Media Contact:
Baxter Phillips,
III
Senior Director Corporate Development
804-747-6026
Baxter.Phillips@Osteologix.com
